

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities, nor is it intended to invite any such offer or invitation. This announcement or any copy thereof may not be directly or indirectly brought into or distributed in the United States (including its territories and possessions, any state of the United States and the District of Columbia). In particular, this announcement does not constitute and is not an offer to sell any securities or a solicitation of an offer to purchase or subscribe for any securities in the United States or elsewhere. Securities may not be offered or sold in the United States unless registered or exempted from registration under the United States Securities Act of 1933, as amended. Any public offering of securities in the United States will be made only by means of a prospectus, which may be obtained from the issuer or the seller of the securities and contains detailed information about the issuer and its management as well as financial information. The Company does not intend to make a public offering of the securities referred to in this announcement in the United States.



**UNISOUND AI TECHNOLOGY CO., LTD.**

**雲知聲智能科技股份有限公司**

(A joint stock company incorporated in the People's Republic of China with limited liability)  
**(Stock Code: 9678)**

## **PLACING OF NEW H SHARES UNDER GENERAL MANDATE**

**Sole Overall Coordinator and Sole Placing Agent**



The Board is pleased to announce that on January 16, 2026 (before trading hours of the Stock Exchange), the Company and the Placing Agent entered into the Placing Agreement, pursuant to which the Company has agreed to appoint the Placing Agent and the Placing Agent has agreed to act as the agent for the Company and on a best effort basis, to procure not less than six (6) independent Placees to subscribe for 780,000 new H Shares at the Placing Price of HK\$252.00 per H Share.

The Placing Shares represent approximately 1.87% of the H Shares in issue and approximately 1.10% of the total number of Shares in issue as at the date of this announcement, and approximately 1.84% of the H Shares and approximately 1.08% of the total number of Shares in issue as enlarged by the allotment and issuance of the Placing Shares (assuming that except for the Placing Shares allotted and issued, there is no change in the issued Shares of the Company from the date of this announcement up to the Completion Date). The total nominal value of the Placing Shares under the Placing will be RMB780,000.

The Placing Price of HK\$252.00 per H Share represents:

- (i) a discount of approximately 16.00% to the closing price of HK\$300.00 per H Share as quoted on the Stock Exchange on January 15, 2026 (being the Last Trading Day and the date on which the Placing Price is fixed); and
- (ii) a discount of approximately 18.13% to the average closing price of HK\$307.80 per H Share as quoted on the Stock Exchange for the last five consecutive trading days up to and including January 14, 2026 (being the date immediately prior to (but excluding) the Last Trading Day).

Assuming all the Placing Shares are fully placed, the gross proceeds and net proceeds (after deducting the commission and estimated expenses) from the Placing are expected to be HK\$196.56 million and approximately HK\$191.69 million, respectively. On such basis, the net issue price will be approximately HK\$245.76 per Placing Share.

The Placing Shares will be issued by the Company under the General Mandate.

An application will be made by the Company to the Stock Exchange for the listing of, and the permission to deal in, the Placing Shares.

**As the Completion of the Placing is subject to the fulfilment of certain conditions precedent under the Placing Agreement, the Placing may or may not proceed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.**

## **PLACING OF NEW H SHARES UNDER GENERAL MANDATE**

The Board is pleased to announce that on January 16, 2026 (before trading hours of the Stock Exchange), the Company and the Placing Agent entered into the Placing Agreement, pursuant to which the Company has agreed to appoint the Placing Agent and the Placing Agent has agreed to act as the agent for the Company and on a best effort basis, to procure not less than six (6) independent Placees to subscribe for 780,000 new H Shares at the Placing Price of HK\$252.00 per H Share.

## **PLACING AGREEMENT**

The principal terms of the Placing Agreement are set out below:

### **Date**

January 16, 2026 (before trading hours of the Stock Exchange)

### **Parties**

- (i) the Company; and
- (ii) the Placing Agent.

To the best of the knowledge, information and belief of the Directors and the Placing Agent, having made all reasonable enquiries, the Placing Agent and its ultimate beneficial owner(s) is an Independent Third Party.

## **Placing**

Pursuant to the Placing Agreement, the Placing Agent has agreed to act as the agent for the Company and on a best effort basis, to procure not less than six (6) independent Placees to subscribe for 780,000 new H Shares at the Placing Price of HK\$252.00 per H Share.

## **Placing Shares**

Under the terms of the Placing Agreement and subject to the conditions of Placing Agreement, the Company will issue 780,000 new H Shares with a nominal value of RMB1.00 each in the issued H share capital of the Company.

The Placing Shares represent approximately 1.87% of the H Shares in issue and approximately 1.10% of the total number of Shares in issue as at the date of this announcement, and approximately 1.84% of the H Shares and approximately 1.08% of the total number of Shares in issue as enlarged by the allotment and issuance of the Placing Shares (assuming that except for the Placing Shares allotted and issued, there is no change in the issued Shares of the Company from the date of this announcement up to the Completion Date). The total nominal value of the Placing Shares under the Placing will be RMB780,000.

## **Placees**

The Placing Shares will be placed by the Placing Agent, on a best effort basis, to not less than six (6) Placees who are independent individual, professional or institutional investor who and whose ultimate beneficial owners are Independent Third Parties (the “**Placee(s)**”). It is not expected that any Placee will become a substantial shareholder (as defined under the Listing Rules) of the Company immediately after the Completion of the Placing.

## **Placing Price**

The Placing Price of HK\$252.00 per H Share represents:

- (i) a discount of approximately 16.00% to the closing price of HK\$300.00 per H Share as quoted on the Stock Exchange on January 15, 2026 (being the Last Trading Day and the date on which the Placing Price is fixed); and
- (ii) a discount of approximately 18.13% to the average closing price of HK\$307.80 per H Share as quoted on the Stock Exchange for the last five consecutive trading days up to and including January 14, 2026 (being the date immediately prior to (but excluding) the Last Trading Day).

The Placing Price was determined based on the prevailing market prices of the H Shares and was arrived at by the Company and the Placing Agent through arm's length negotiation. The Directors consider that the Placing Price is fair and reasonable and the Placing is in the interests of the Company and the Shareholders as a whole.

## **Ranking of Placing Shares**

The Placing Shares, when allotted and issued by the Company under the General Mandate pursuant to the Placing Agreement, shall rank *pari passu* in all respects with other H Shares then in issue and be free and clear from all encumbrances and with all rights attaching thereto as at date of issue of the Placing Shares, including the right to receive all dividends and other distributions which may be declared, made or paid in respect of the Placing Shares, the record date for which shall fall on or after the date of issue of the Placing Shares.

## **Conditions of the Placing**

Completion of the Placing is conditional upon the fulfilment or waiver (if applicable) of the following conditions:

- (a) the Listing Approval having been granted by the Stock Exchange and such Listing Approval not subsequently being revoked prior to the delivery of the definitive share certificate(s) representing the Placing Shares;
- (b) approvals, permissions, actions, authorisations and filings required to be completed prior to the Completion for the performance by the Company of its obligations under the Placing Agreement and the matters contemplated by the Placing Agreement have been obtained and are in full force and effect;
- (c) the Placing Agent having received on the Completion Date the final draft or substantially complete draft of the CSRC Filings, such drafts to be in form and substance reasonably satisfactory to the Placing Agent; and
- (d) the Company's representations and warranties made pursuant to the Placing Agreement being true and accurate and not misleading as of the date of the Placing Agreement and the Completion Date.

Save for condition (d) above, which are waivable by the Placing Agent, all other conditions are not waivable at all time. In the event of any of the conditions above not having been fulfilled or not waived (as the case may be) on or prior to 4:00 p.m. (Hong Kong time) on Completion Date or such later time as may be agreed in writing between the Company and the Placing Agent, all rights, obligations and liabilities of the parties in relation to the Placing shall cease and determine and none of the Parties shall have any claim against the other, save for antecedent breaches.

## **Completion of the Placing**

Subject to the fulfilment or waiver (as the case may be) of the conditions set out above, the Completion shall take place at or before 4:00 p.m. on the Completion Date.

## **GENERAL MANDATE TO ISSUE THE PLACING SHARES**

The Placing Shares will be issued by the Company under the General Mandate, pursuant to which the Board is authorized to allot issue, and deal with shares not exceeding 20% of the total number of issued Shares of the Company (excluding treasury shares) as at the date of the extraordinary general meeting of the Company held on December 10, 2025.

As of the date of this announcement, the Company has not issued any new Shares under the General Mandate. The Board has approved the Placing under the General Mandate and the Placing does not require further Shareholders' approval.

## **LOCK-UP**

Pursuant to the Placing Agreement, the Company hereby undertakes to the Placing Agent that: it will not allot or issue or offer to allot or issue or grant any option, right or warrant to subscribe (either conditionally or unconditionally, or directly or indirectly, or otherwise) any Shares or any interests in Shares or any securities convertible into or exercisable or exchangeable for or substantially similar to any Shares or interest in Shares during the period commencing on the date of the Placing Agreement up to 60 days after the Completion Date, unless the prior written consent of the Placing Agent having been obtained, other than pursuant to: (i) any exercise of any convertible notes or warrants or options in issue at the date of the Placing Agreement or any other conversion or subscription rights existing as at the date of the Placing Agreement; (ii) exercise of any share options granted pursuant to the share option scheme of the Company adopted pursuant to the Listing Rules as at the date of the Placing Agreement; (iii) exercise of any restricted share units granted pursuant to the restricted share unit scheme of the Company adopted pursuant to the Listing Rules as at the date of the Placing Agreement; (iv) any scrip dividend scheme; or (v) any allotment and issue of the Placing Shares pursuant to the Placing Agreement. The Company will not agree (conditionally or unconditionally) to enter into or effect any such transaction with the same economic effect as any of the transactions described above.

## **REASONS FOR AND USE OF THE PROCEEDS FROM THE PLACING**

Upon the Completion of the Placing, the proceeds raised will further enhance the Company's financial strength, market competitiveness and comprehensive strength, and promote the long-term healthy and sustainable development of the Company.

Assuming all the Placing Shares are fully placed, the gross proceeds and net proceeds (after deducting the commission and estimated expenses) from the Placing are expected to be HK\$196.56 million and approximately HK\$191.69 million, respectively. On such basis, the net issue price will be approximately HK\$245.76 per Placing Share.

The net proceeds from the Placing are proposed to be used for the following purposes:

The Company will receive net proceeds from the Placing of approximately HK\$191.69 million, of which (i) approximately 50% will be used to enhance the Company's research and development ("R&D") capabilities; (ii) approximately 40% will be used to invest in emerging business opportunities; and (iii) 10% will be used to replenish working capital and general corporate purposes. Specifically,

- (i) approximately 50% will be used to enhance the Company's R&D capabilities, with the detailed allocation as follows:
  - (a) strengthening Atlas AI infrastructure for agent application support: approximately 24% will be allocated to strengthening the Atlas AI infrastructure for agent application support. The Company will continue to optimise its supercomputing platform to improve the efficiency of AI model training and maintain its leadership in core technologies. The Company will further enhance the inference infrastructure to support the rapid industrialisation of large models.
  - (b) upgrading the UniBrain with agent-centric capabilities: approximately 20% will be used to upgrade the UniBrain, focusing on continuous model iteration and data closed-loop evolution to meet the changing needs of various application scenarios. The Company will prioritise agent technology R&D and platform development, especially for large models and agent technologies in vertical industries such as healthcare, insurance, and transportation, to maintain its core product and technology competitiveness and build data barriers. In addition, the Company will strengthen the multi-language and multimodal capabilities of large models, achieve distillation and optimisation of on-device large models, and develop cost-effective on-device solutions to support the growing demand for upgrades in large model and agent technologies, and to maintain competitive advantage.
  - (c) talent cultivation and joint R&D: approximately 6% will be allocated to talent cultivation and joint R&D. For internal talent training, the Company will increase the use of AI tools in analysis, planning, design, and development to comprehensively improve overall R&D quality and efficiency of the Company. In addition to maintaining domestic academic collaborations, the Company will strengthen cooperation with overseas institutions, including those in Hong Kong, to enhance international technical collaboration and talent development.
- (ii) business opportunity exploration: approximately 40% will be allocated to investing in emerging business opportunities. The Company plans to expand its product development and sales teams, promote and market its products through marketing activities such as industry exhibitions, and establish its brand image and influence in the following two areas:
  - (a) regional AI infrastructure and application platforms: there is a strong demand for regional platforms and applications, such as regional healthcare information service platforms led by regional and specialised health commissions, government information service platforms with distinctive features, and cultural tourism information platforms. The innovation and upgrade of these platforms have created rigid demand for platform-level AI capabilities, including computing power upgrades, large model services, and agent services.

- (b) industry agent products: with the rise of multimodal large models and professional agents, digital employees and experts in specialised fields are becoming increasingly feasible in more industries. The Company has developed relevant products and will further promote and expand industry penetration.
- (iii) working capital and general corporate purposes: approximately 10% will be allocated to talent recruitment and retention, working capital, and other administrative purposes to support its business operations.

Although as at December 31, 2025, HK\$124.78 million of the Net Proceeds (as defined below) remained unutilized, these funds will continue to be used in accordance with the intended use set out in the Prospectus. Given the Company's strong track record and ongoing growth initiatives, the Company believes the Placing provides an opportunity to further strengthen the Company's financial strength for capitalizing on the current growth opportunities.

In view of the above, the Directors consider that the terms of the Placing Agreement (including but not limited to the Placing Price and the Placing commission payable to the Placing Agent) are fair and reasonable and the Placing is in the interests of the Company and its Shareholders as a whole.

## **EQUITY FUND RAISING ACTIVITY IN THE PAST TWELVE MONTHS**

On June 30, 2025, the H Shares were listed on the Main Board of the Stock Exchange. After deducting underwriting fees, commissions and other offering expenses, the net proceeds from the Global Offering and the exercise of the Over-allotment Option (as defined in the Prospectus) amounted to approximately HK\$236.94 million (the "**Net Proceeds**"), which will be utilized for the purposes as set out in the Prospectus.

The intended and actual usage of the Net Proceeds as at December 31, 2025 are set out below:

Intended use of the Net Proceeds	Net proceeds from the listing available (HK\$ million)	Percentage of use of proceeds raised (%)	Actual net amount utilized as at December 31, 2025			Unutilized net amount (HK\$ million)	Expected timeline as at December 31, 2025 for fully utilizing unutilized net amount (HK\$ million)	Expected timeline as disclosed in the prospectus
			(HK\$ million)	On or before June 30, 2030	Within 5 years after listing			
Enhance R&D capabilities	108.05	45.6	83.45	24.60	On or before June 30, 2030	Within 5 years after listing		
Invest in emerging business opportunities and increase the adoption and penetration of our products in industry verticals and scenarios	111.36	47.0	13.09	98.27	On or before June 30, 2030	Within 5 years after listing		
Working capital and general corporate use	17.53	7.4	15.62	1.91	—	—	—	—
<b>Total</b>	<b>236.94</b>	<b>100.0</b>	<b>112.16</b>	<b>124.78</b>	<b>—</b>	<b>—</b>	<b>—</b>	<b>—</b>

*Note:* Due to rounding, there may be a difference between the sum of the individual sub-values and the total amount. The expected timeline for fully utilizing unutilized net amount is based on the Company's forecasts, which is subject to the current and future development of the market conditions.

Save as disclosed above, the Company has not carried out any equity fund raising activities in the past 12 months immediately preceding the date of this announcement.

# IMPACT OF THE PLACING ON THE SHAREHOLDING STRUCTURE OF THE COMPANY

The table below sets forth the shareholding structure of the Company (i) as at the date of this announcement; and (ii) immediately after the Completion of the Placing, assuming the Placing will be completed in full and there will be no other changes in the total share capital in issue of the Company from the date of this announcement up to the Completion of the Placing.

	As at the date of this announcement	Approximate percentage of the total number of Shares in issue <sup>Note 1</sup>	Immediately after the Completion of the Placing	Approximate percentage of the total number of Shares in issue <sup>Note 1</sup>
<b><i>Domestic unlisted Shares</i></b>				
Core connected persons <sup>Note 2</sup>	16,658,441	23.40%	16,658,441	23.15%
Other holders of domestic unlisted Shares	8,336,620	11.71%	8,336,620	11.58%
<b>Sub-total</b>	<b>24,995,061</b>	<b>35.11%</b>	<b>24,995,061</b>	<b>34.73%</b>
<b><i>Unlisted Foreign Shares</i></b>				
<b>Ming Fu Investments Limited<sup>Note 3</sup></b>	<b>4,570,649</b>	<b>6.42%</b>	<b>4,570,649</b>	<b>6.35%</b>
<b><i>H Shares</i></b>				
H Shares held by core connected persons <sup>Note 4</sup>	15,865,662	22.29%	15,865,662	22.05%
H Shares held by other public H Shareholders	25,756,221	36.18%	25,756,221	35.79%
H Shares held by Placees	—	—	780,000	1.08%
<b>Sub-total</b>	<b>41,621,883</b>	<b>58.47%</b>	<b>42,401,883</b>	<b>58.92%</b>
<b>Total</b>	<b>71,187,593</b>	<b>100.00%</b>	<b>71,967,593</b>	<b>100.00%</b>

*Notes:*

1. The percentages have been rounded up to the nearest two decimal places and any discrepancy between the totals and sums of amounts listed in the table is due to rounding.
2. This represents the sum of (i) 16,481,964 domestic unlisted Shares in which Dr. Huang Wei, Dr. Liang Jia'en and Dr. Kang Heng, executive Directors of the Company, were deemed to be interested by virtue of their acting-in-concert arrangement. Dr. Liang Jia'en directly held 1,835,658 domestic unlisted Shares, and Dr. Kang Heng directly held 1,101,395 domestic unlisted Shares. Yunsi Shangyi directly held 11,697,500 domestic unlisted Shares, while Yunchuang Hudong directly held 1,847,411 domestic unlisted Shares. The general partner of each of Yunsi Shangyi and Yunchuang Hudong is Tianjin Yunsheng, which is held as to 99% of equity interests by Dr. Huang Wei and 1% of equity interests by Mr. Liu Shengping, the executive Director of the Company. Dr. Huang Wei is also the largest limited partner of Yunsi Shangyi with 82.59% partnership interest. Each of Yunsi Shangyi and Yunchuang Hudong is controlled by Dr. Huang Wei. As such, each of Tianjin Yunsheng and Dr. Huang Wei is deemed to be interested in the Shares held by Yunsi Shangyi and Yunchuang Hudong for the purpose of Part XV of the SFO; (ii) 176,477 domestic unlisted Shares of the Company in which Mr. Li Zhichao, non-executive Director of the Company, was deemed to be interested.

3. Ming Fu Investments Limited (a private joint stock company incorporated in Hong Kong) is directly held as to 96.94% by Qiming Venture Partners III, L.P., and the general partner of Qiming Venture Partners III, L.P. is Qiming GP III, L.P., and the general partner of which is Qiming Corporate GP III, Ltd., an exempted company incorporated in the Cayman Islands which is an Independent Third Party. As such, each of Qiming Venture Partners III, L.P., Qiming GP III, L.P. and Qiming Corporate GP III, Ltd. were deemed to be interested in the unlisted foreign Shares held by Ming Fu Investments Limited.
4. This represents the sum of (i) 7,063,697 H Shares in which Dr. Huang Wei, Dr. Liang Jia'en and Dr. Kang Heng, executive Directors of the Company, were deemed to be interested by virtue of their acting-in-concert arrangement. Dr. Liang Jia'en directly held 786,710 H Shares, and Dr. Kang Heng directly held 472,026 H Shares. Yunsi Shangyi directly held 5,013,214 H Shares, while Yunchuang Hudong directly held 791,747 H Share. The general partner of each of Yunsi Shangyi and Yunchuang Hudong is Tianjin Yunsheng, which is held as to 99% of equity interests by Dr. Huang Wei and 1% of equity interests by Mr. Liu Shengping, the executive Director of the Company. Dr. Huang Wei is also the largest limited partner of Yunsi Shangyi with 82.59% partnership interest. Each of Yunsi Shangyi and Yunchuang Hudong is controlled by Dr. Huang Wei. As such, each of Tianjin Yunsheng and Dr. Huang Wei is deemed to be interested in the Shares held by Yunsi Shangyi and Yunchuang Hudong for the purpose of Part XV of the SFO; (ii) 152,097 H Shares of the Company in which Mr. Li Zhichao, non-executive Director of the Company, was deemed to be interested; and (iii) 8,649,868 H Shares of the Company in which Li Shujun was deemed to be interested. TBP Sound Cloud Holdings (HK) Limited beneficially owned 6,202,020 H Shares, all of which were owned as to 100% by TBP Sound Cloud Holdings Limited. TBP Sound Cloud Holdings Limited is owned as to 100% by Trustbridge Partners V, L.P., while Trustbridge Partners V, L.P. is owned as to 100% by TB Partners GP5, L.P., which is owned as to 100% by TB Partners GP5 Limited. TBP Sound Cloud Holdings (HK) II Limited beneficially owned 2,447,848 H Shares, all of which were owned as to 100% by TBP Sound Cloud Holdings II Limited. TBP Sound Cloud Holdings II Limited is owned as to 100% by Trustbridge Partners VII, L.P., while Trustbridge Partners VII, L.P. is owned as to 100% by TB Partners GP7, L.P., which is owned as to 100% by TB Partners GP7 Limited. All of TB Partners GP5 Limited and TB Partners GP7 Limited were owned as to 100% by Li Shujun. As such, Li Shujun is deemed to be interested in 6,202,020 H Shares held by TBP Sound Cloud Holdings (HK) Limited and 2,447,848 H Shares held by TBP Sound Cloud Holdings (HK) II Limited for the purpose of Part XV of the SFO.

The Directors confirm that, immediately after the Completion of the Placing, the public float of the Company will be no less than 25% of the Company's issued share capital as enlarged by the Placing (assuming that the Placing Shares are fully placed and except for the Placing Shares allotted and issued, there is no change in the issued Shares of the Company from the date of this announcement up to the date of Completion of the Placing).

## **APPLICATION FOR LISTING**

An application will be made by the Company to the Stock Exchange for the listing of, and the permission to deal in, the Placing Shares.

## **FILING WITH REGULATORY AUTHORITIES IN THE PRC**

After the Placing Shares are issued and listed on the Stock Exchange, the Company will file with the regulatory authorities in the PRC in accordance with the relevant applicable laws and regulations, including the CSRC Filings.

## **AMENDMENTS TO THE ARTICLES OF ASSOCIATION**

Upon Completion of the Placing, the registered capital and total number of the Shares of the Company will be changed to RMB71,967,593 and 71,967,593 Shares, respectively. To reflect such changes in the registered capital and total share capital of the Company, corresponding amendments will be made to the Articles of Association (the "**Amendments to the Articles of Association**").

In accordance with the resolution in relation to the General Mandate passed at the extraordinary general meeting of the Company held on December 10, 2025, the general meeting of the Company has authorized the Board and for the Board to further authorize the chairman of the Board and his authorized persons (unless otherwise provided by relevant laws and regulations in respect of matters of sub-delegation) to make corresponding amendments to the Articles of Association as it considers appropriate and necessary to reflect the registered capital and total share capital of the Company as a result of issuance of additional Shares under the General Mandate. As such, the Amendments to the Articles of Association do not require further Shareholders' approval and will become effective from the date of Completion of the Placing.

**As the Completion of the Placing is subject to the fulfilment of certain conditions precedent under the Placing Agreement, the Placing may or may not proceed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.**

## **DEFINITIONS**

In this announcement, unless the context otherwise requires, the following expressions shall have the following meanings:

“Articles of Association”	the articles of association of the Company (as amended from time to time)
“Board”	the board of directors of the Company
“Completion”	the completion of the Placing on the terms and subject to the conditions set out in the Placing Agreement
“Completion Date”	expected to be the two (2) Business Days after the date upon which the Listing Approval has been granted but in any event no later than January 23, 2026, or such other date as may be agreed in writing between the Placing Agent and the Company
“Company”	Unisound AI Technology Co., Ltd. (雲知聲智能科技股份有限公司), a company initially established in the PRC with limited liability on June 29, 2012, and converted into a joint stock company with limited liability on June 24, 2019, and the H shares of which were listed on the Main Board of the Stock Exchange (stock code: 9678) on June 30, 2025
“connected persons”	has the meaning ascribed to it under the Listing Rules

“Controlling Shareholders”	has the meaning ascribed thereto in the Listing Rules, unless the context otherwise requires, refer to Dr. Liang Jia’en, Dr. Huang Wei, Dr. Kang Heng, Tianjin Yunsheng, Yunsi Shangyi and Yunchuang Hudong
“core connected persons”	has the meaning ascribed to it under the Listing Rules
“CSRC”	China Securities Regulatory Commission (中國證券監督管理委員會)
“CSRC Filings”	the CSRC Filing Report and any relevant supporting materials to be filed with the CSRC
“CSRC Filing Report”	the filing report in relation to the Placing and any transactions contemplated by the Placing Agreement to be filed with the CSRC
“CSRC Filing Rules”	the Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies issued by the CSRC and supporting guidelines issued by the CSRC (effective from 31 March 2023), as amended, supplemented or otherwise modified from time to time
“Director(s)”	the director(s) of the Company
“General Mandate”	the general mandate granted to the Directors to allot, issue or otherwise deal with Shares (including any sale or transfer of treasury shares) not exceeding 20% of the total number of issued Shares in issue (excluding any treasury shares), pursuant to a resolution of the Shareholders passed at the extraordinary general meeting of the Company held on December 10, 2025
“Global Offering”	the Hong Kong Public Offering and the International Offering (each as defined in the Prospectus)
“Group”	the Company and its subsidiaries from time to time
“H Share(s)”	the overseas listed foreign Share(s) in the share capital of the Company, with a nominal value of RMB1.00 each, which are listed on the Stock Exchange
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“HK\$”	Hong Kong dollars, the lawful currency of Hong Kong
“Independent Third Party(ies)”	any person(s) or entity(ies) who is not a connected person of the Company within the meaning of the Listing Rules

“Last Trading Date”	January 15, 2026, being the last trading day prior to the signing of the Placing Agreement, which took place before trading hours
“Listing Approval”	the written confirmation issued by the listing committee of the Stock Exchange granting the listing of, and permission to deal in, the Placing Shares
“Listing Date”	June 30, 2025, on which the H Shares were listed and on which dealings in the H Shares were first permitted to commence on the Stock Exchange
“Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited
“Placing”	the placing of the Placing Shares by or on behalf of Placing Agent on the terms and subject to the conditions set out in the Placing Agreement
“Placing Agent”	Guotai Junan Securities (Hong Kong) Limited
“Placing Agreement”	the placing agreement entered into between the Company and the Placing Agent on January 16, 2026 in relation to the Placing under the General Mandate
“Placing Price”	HK\$252.00 per Placing Share
“Placing Shares”	780,000 new H Shares to be allotted and issued under the terms and conditions of the Placing Agreement
“PRC” or “China”	the People’s Republic of China excluding, for the purposes of this announcement, Hong Kong, the Macau Special Administrative Region of the People’s Republic of China and Taiwan
“Prospectus”	the prospectus of the Company dated June 20, 2025
“RMB”	Renminbi, the lawful currency of the PRC
“Securities Act”	the United States Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder
“SFO”	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)
“Share(s)”	the ordinary share(s) in the capital of the Company with a nominal value of RMB1.00 each, comprising the domestic unlisted Shares, unlisted foreign Shares and the H Shares

“Shareholder(s)”	holder(s) of the Share(s)
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“subsidiary(ies)”	has the meaning ascribed to it under the Listing Rules
“substantial shareholder(s)”	has the meaning ascribed to it under the Listing Rules
“Tianjin Yunsheng”	Tianjin Yunsheng Information Technology Co., Ltd. (天津市雲盛信息技術有限公司), a company established in the PRC on March 3, 2016 and one of the Controlling Shareholders
“treasury shares”	has the meaning ascribed to it under the Listing Rules
“United States” or “U.S.”	has the meaning ascribed to it under Rule 902 of Regulation S under the Securities Act
“Unlisted Shares”	unlisted ordinary Share(s) issued by the Company, with a nominal value of RMB1.00 each, which is/are not listed or traded on any stock exchange
“Yunchuang Hudong”	Beijing Yunchuang Hudong Investment Management Consulting Partnership (Limited Partnership) (北京雲創互動投資管理諮詢合夥企業 (有限合夥) ), a limited partnership established in the PRC on May 13, 2015, and one of the employee incentive platforms and Controlling Shareholders
“Yunsi Shangyi”	Yunsi Shangyi (Tianjin) Enterprise Management Partnership (Limited Partnership) (雲思尚義 (天津) 企業管理合夥企業 (有限合夥) ), a limited partnership established in the PRC on March 28, 2016 and one of the Controlling Shareholders
“%”	per cent

By Order of the Board  
**Unisound AI Technology Co., Ltd.**  
**Dr. Huang Wei**  
*Executive Director and General Manager*

Beijing, the PRC  
 January 16, 2026

*As of the date of this announcement, the board of directors of the Company comprises: (i) Dr. Liang Jia'en, Dr. Huang Wei, Dr. Kang Heng, Dr. Li Xiaohan and Dr. Liu Shengping as executive directors; (ii) Mr. Li Zhichao and Mr. Li Ang as non-executive directors; and (iii) Mr. Hu Jianjun, Dr. Fan Jian, Dr. Jin Huihua and Dr. Zhang Kun as independent non-executive directors.*